Clinical Trial Update: To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial completed to determine the maximum tolerated dose of BAY79-4620 in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• BAY79-4620

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED